Media about us

• Venter Pharma und NovaMedica unterzeichnen Vertrag für die Vermarktung eines neuen Tests für die Diagnose von Laktose-Intoleranz in Russland

  12 December 2013 PHARMA-ZEITUNG.DE

  

  NovaMedica LLC, ein russisches Pharmaunternehmen, und Venter Pharma SL, ein spanisches Unternehmen, das innovative diagnostische Systeme entwickelt, haben eine Partnerschaftsvereinbarung unterzeichnet, im Rahmen derer NovaMedica die Exklusivrechte erhält, um LacTEST®, eine neue Technologie für die Diagnose von Laktose-Intoleranz in Russland und der GUS (Gemeinschaft unabhängiger Staaten) zu vermarkten.

• Venter Pharma y Novamedica, acuerdo de distribución de LacTest en Rusia

  12 December 2013 PMFARMA

  

  LacTEST es un producto best-in-class de su categoría para el diagnóstico de la intolerancia a la lactosa en individuos de distintos grupos de edad. El test tiene aplicaciones en gastroenterología clínica y ha sido aprobado para su distribución en España y Alemania.

• Venter Pharma and NovaMedica Sign Agreement to Commercialize New Lactose Intolerance Test in Russia

  11 December 2013 FierceMedicalDevices

  

  NovaMedica LLC, a Russian pharmaceutical company, and Venter Pharma SL, a Spanish company, developing innovative diagnostic systems, have signed a partnership agreement that grants NovaMedica exclusive rights to commercialize a new technology for the diagnosis of lactose intolerance, LacTEST®, in Russia and the Community of Independent States (CIS).

   

• NovaMedica unterzeichnet Vertriebsvereinbarung mit Aptalis Pharma zur Entwicklung und Vermarktung von Magen-Darm-Pharmazeutika in Russland

  06 December 2013 PHARMA-ZEITUNG.DE

  

  Das russische Pharmaunternehmen NovaMedica LLC hat eine Partnerschaftsvereinbarung mit dem führenden Hersteller von Spezialpharmazeutika, Aptalis Pharma, unterzeichnet, um innovative und wirksame Behandlungsoptionen für einen bislang ungedeckten medizinischen Bedarf bereitzustellen und drei der neuartigen gastrointestinalen Pharmaprodukte von Aptalis Pharma zu entwickeln und in Russland zu vermarkten.

• NovaMedica signe, avec Aptalis Pharma, un accord de distribution visant à développer et à commercialiser, en Russie, des produits pharmaceutiques pour le traitement des troubles gastro-intestinaux

  06 December 2013 BFMTV

  

  NovaMedica LLC, une société pharmaceutique russe, a signé un accord de partenariat avec Aptalis Pharma, une société pharmaceutique spécialisée de premier plan, qui fournit des thérapies novatrices efficaces répondant aux besoins médicaux non-satisfaits. Cet accord vise à développer et commercialiser, en Russie, un portefeuille de trois nouveaux produits pharmaceutiques d'Aptalis Pharma destinés au traitement des troubles gastrointestinaux.

• NovaMedica to distribute Aptalis products in Russia

  06 December 2013 The Pharma Letter

  

  Russian drugmaker NovaMedica has signed a partnership agreement with privately-held US firm Aptalis Pharma, to develop and commercialize a portfolio of three of Aptalis Pharma’s novel gastrointestinal pharmaceutical products in Russia. Under the agreement, financial terms of which were not disclosed, NovaMedica will work towards to completing the requirements for regulatory approval of the products in Russia. Subject to obtaining approvals, Aptalis’ pharmaceutical products are expected to come to market in 2014-2015.

• NovaMedica, Aptalis Sign Russian Distribution Pact

  06 December 2013 Contact Pharma

  

  NovaMedica has signed a partnership agreement with Aptalis Pharma to develop and commercialize three of Aptalis' gastrointestinal products in Russia. The products include Pylera, indicated for the eradication of Helicobacter Pylori in patients with gastric or duodenal ulcer; Lacteol, a product derived from a human strain of Lactobacillus LB for use in patients with diarrhea; and Panzytrat, a formulation of pancreatic enzymes indicated for maldigestion due to exocrine pancreatic insufficiency related to cystic fibrosis, chronic pancreatitis, major pancreatic resection, gastric resection.  

• Kremlin seeks to monetise the field of science

  17 October 2013 Isabel Gorst, Financial Times

  

  Change is coming to the 289-year-old Russian Academy of Sciences. Once famous for work that won it 18 Nobel Prizes and helped put the first man in space, the Academy has failed to keep up with the times.

• NovaMedica Opens Plant in Russia

  06 August 2013 Industry Week

  

  Plant is part of local government’s strategy to develop pharmaceutical cluster.

• RusnanoMedInvest invested in American technology for vision correction

  02 August 2013 Venture News

  

  American venture Fund Domain Associates, venture investment company RusnanoMedInvest (RMI, affiliate of ROSNANO) and a group of co-investors invest $55M in the company ReVision Optics, Inc., which develops innovation medical technology for treatment of age-dependent visual acuity decrement.